Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA SETS ASIDE JULY 28 FOR ADDITIONAL ZOVIRAX Rx-TO-OTC SWITCH REVIEW

This article was originally published in The Tan Sheet

Executive Summary

FDA SETS ASIDE JULY 28 FOR ADDITIONAL ZOVIRAX Rx-TO-OTC SWITCH REVIEW by its Nonprescription Drugs Advisory Committee and Antiviral Drugs Advisory Committee, according to an FDA list of tentative meeting dates. FDA has set a public hearing for May 19 from 8 a.m. to 3:30 p.m. to solicit opinions from scientists, professional groups and consumers on issues related to the over- the-counter availability of Burroughs Wellcome's Zovirax (acyclovir) for the treatment of recurrent genital herpes ("The Tan Sheet" March 14, p. 1). Following the hearing, the two advisory committees will meet from 3:30 p.m. to 6 p.m.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS082749

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel